Journal of Indian Academy of Oral Medicine and Radiology

ORIGINAL ARTICLE
Year
: 2021  |  Volume : 33  |  Issue : 3  |  Page : 236--241

Colchicine as a therapeutic drug in the management of oral submucous fibrosis - A randomized clinical study


Somisetty V M. Mounika1, Rakesh K Manne1, Natarajan Kannan1, Swapna S Beeraka1, Prathi V Sarath1, Kanamarlapudi V Saikiran2 
1 Department of Oral Medicine and Radiology, Narayana Dental College and Hospital, Nellore, Andhra Pradesh, India
2 Department of Pediatric and Preventive Dentistry, SVS Institute of Dental Sciences, Mahabubnagar, Telangana, India

Correspondence Address:
Dr. Somisetty V M. Mounika
Post-Graduate Student, Department of Oral Medicine and Radiology, Narayana Dental College and Hospital, Nellore, Andhra Pradesh - 524 003
India

Aim: The present study was planned to clinically determine the effectiveness of colchicine as a monotherapy in oral submucous fibrosis (OSMF) patients. Materials and Methods: Thirty OSMF patients were enrolled in the study and randomly divided into two groups by permuted-block randomization. Group A: Patients were treated with 0.5 mg colchicine (Goutnil) tablets twice daily for 3 months. Whereas, in Group B, intralesional injection of dexamethasone 2 mL, hyaluronidase 1,500 IU with 2 mL lignocaine HCl biweekly for 4–6 weeks were given. For all the individuals, baseline parameters like mouth opening, buccal mucosal flexibility, burning sensation, and tongue protrusion were recorded and reassessment was done at 1, 3, and 6 months followed by statistical analysis. Results: A significant decrease in the Visual Analogue Scale (VAS) score for severity of burning sensation was observed in Group A whereas mouth opening and tongue protrusion were higher in Group B patients. Statistically significant differences in the buccal mucosal flexibility were appreciable in the intragroup comparisons of both the groups from baseline to 6-month follow-up. Conclusion : Colchicine can be suggested as an adjuvant drug for reducing the burning sensation for the OSMF patients in whom steroids are contraindicated.


How to cite this article:
M. Mounika SV, Manne RK, Kannan N, Beeraka SS, Sarath PV, Saikiran KV. Colchicine as a therapeutic drug in the management of oral submucous fibrosis - A randomized clinical study.J Indian Acad Oral Med Radiol 2021;33:236-241


How to cite this URL:
M. Mounika SV, Manne RK, Kannan N, Beeraka SS, Sarath PV, Saikiran KV. Colchicine as a therapeutic drug in the management of oral submucous fibrosis - A randomized clinical study. J Indian Acad Oral Med Radiol [serial online] 2021 [cited 2021 Dec 7 ];33:236-241
Available from: https://www.jiaomr.in/article.asp?issn=0972-1363;year=2021;volume=33;issue=3;spage=236;epage=241;aulast=M.;type=0